Jan 11, 2013 6:24 AM PST
|
|
NasdaqGS: GERN Stock Quote
| Last Trade: | 1.18 | Day's Range: | 1.12 - 1.2299 | |
| Trade Time: | 12:52pm | 52wk Range: | 0.91 - 2.99 | |
| Change: | +0.03 (+2.61%) | Volume: | 762,579 | |
| Prev Close: | 1.15 | Avg Vol (3m): | 750,716 | |
| Open: | 1.14 | Market Cap: | 153.9M | |
| Bid: | 1.18 x 1,900 | P/E (ttm): | N/A | |
| Ask: | 1.19 x 3,700 | EPS (ttm): | -0.487 | |
| 1y Target Est: | 1.50 | Div & Yield: | 0.00 (N/A) |
NasdaqGS: GERN Overview
Geron Corporation (Geron) is a biopharmaceutical company that is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The Company is advancing telomerase targeted therapies, including an anti-cancer drug and a cancer vaccine, through multiple clinical trials. Geron also develops human embryonic stem cell (hESC)-based therapeutics. The Company is developing anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines. Geron is also researching compounds that transiently activate telomerase in senescent cells to restore cell function for the treatment of injuries and chronic diseases.
Do you know of another great research resource for GERN that belongs here? Please let us know and provide the URL.
